

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event Reported): November 30, 2015

**GREATBATCH, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction of Incorporation)

**1-16137**  
(Commission File Number)

**16-1531026**  
(I.R.S. Employer Identification Number)

**2595 Dallas Parkway, Suite 310, Frisco, Texas**  
(Address of Principal Executive Offices)

**75034**  
(Zip Code)

Registrant's telephone number, including area code: **(716) 759-5600**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**Item 8.01. Other Events.**

On November 30, 2015, Greatbatch, Inc. (the "Company") issued a press release announcing that it has received Premarket Approval (PMA) from the United States Food & Drug Administration for its Algovita spinal cord stimulation system for the treatment of chronic pain of the trunk and limbs. Receipt of this approval reflects the Company's strategic evolution of its product offerings to include the development of complete medical devices.

A copy of the press release announcing the receipt of the approval is attached as Exhibit 99.1 to this report.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press Release dated November 30, 2015

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 30, 2015

GREATBATCH, INC.

By: /s/ MICHAEL DINKINS  
Michael Dinkins  
Executive Vice President and  
Chief Financial Officer

## **Greatbatch Receives FDA Approval of Algovita(R) Spinal Cord Stimulation System**

FRISCO, Texas, Nov. 30, 2015 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE:GB) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Algovita<sup>®</sup> Spinal Cord Stimulation (SCS) System to treat chronic intractable pain of the trunk and/or limbs.

"We are excited to receive PMA approval from the FDA for the Algovita SCS system," said Thomas J. Hook, president and CEO of Greatbatch, Inc. "Algovita's approval not only supports the proposed Nuvectra<sup>™</sup> spin-off, but the system brings to the U.S. market a robust and user-friendly device for patients suffering from chronic pain of the trunk and/or limbs."

The Algovita SCS system is the first FDA-approved product developed by Greatbatch's QiG Group subsidiary. As previously disclosed, Greatbatch is in the process of finalizing the proposed spin-off of QiG Group, LLC, which will be renamed Nuvectra Corporation when the process is completed.

Since its inception in 2008, QiG Group has developed an innovative, broad-based, neurostimulation technology platform. Initially, the company will be focused on the commercialization of the Algovita SCS system, used to treat a variety of neuropathic pain conditions. The Algovita SCS system received CE Mark last year, and is currently in limited release in Europe.

The proposed Nuvectra spin-off is expected to be completed in the first quarter of 2016, subject to the Form 10 registration statement becoming effective.

### **About Greatbatch, Inc.**

Greatbatch, Inc. (NYSE:GB) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, orthopaedics, vascular, advanced surgical and portable medical markets. The company provides innovative, high quality medical technologies that enhance the lives of patients worldwide. In addition, it develops batteries for high-end niche applications in energy, military, and environmental markets. The company's brands include Greatbatch Medical, Lake Region Medical and Electrochem. Additional information is available at [www.greatbatch.com](http://www.greatbatch.com).

CONTACT: Investor Relations Contact:  
Anthony Borowicz  
[tborowicz@greatbatch.com](mailto:tborowicz@greatbatch.com)  
tel 716-759-5809

Media Contact:  
Christopher Knospe  
[cknospe@greatbatch.com](mailto:cknospe@greatbatch.com)  
tel 716-759-5727